Immunotherapy employing CAR T cells designed to target BCMA on myeloma cells has garnered regulatory approval for treating relapsed or refractory MM and has significantly improved the prognosis of patients who have undergone at least four prior lines of therapy and are considered triple-class refractory. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.